Events

VIVA Education Webinar 01 July 2020 web

ST. JUDE-VIVA FORUM: 

5-Year Result of CCCG-ALL-2015 & Dasatinib VS  Imatinib 

in the treatment of Paediatric Ph+ acute Lymphoblastic Leukaemia

Sunday , 7 March 2021
08:00 P.M. - 09: 00 P.M. (Singapore  UTC+8)

 

 

ABOUT THE WEBINAR

๐‰๐จ๐ข๐ง ๐ฎ๐ฌ ๐Ÿ๐จ๐ซ ๐š ๐ฐ๐ž๐›๐ข๐ง๐š๐ซ ๐ฉ๐ซ๐ž๐ฌ๐ž๐ง๐ญ๐ž๐ ๐›๐ฒ ๐ญ๐ก๐ž ๐ฐ๐จ๐ซ๐ฅ๐'๐ฌ ๐›๐ข๐ ๐ ๐ž๐ฌ๐ญ ๐ฌ๐ญ๐ฎ๐๐ฒ ๐ ๐ซ๐จ๐ฎ๐ฉ ๐ข๐ง ๐€๐‹๐‹!
Topic 1 : 5 years result of CCCG-ALL-2015
Topic 2 : Dasatinib VS Imatinib in the treatment of pediatric Ph+ acute lymphoblastic leukemia
 

SYNOPSIS

To determine whether dasatinib given at 80 mg/m2 is more effective than imatinib at 300 mg/m2 to improve event-free survival of children with Philadelphia chromosome-positive ALL, in the context of intensive chemotherapy without prophylactic cranial irradiation.

We analyzed the data in our recently completed China Childrenโ€™s Cancer Group ALL-2015 protocol (CCCG-ALL-2015) which totally omitted prophylactic cranial irradiation and included all acute lymphoblastic leukemia (ALL) patients without exclusion any high-risk subgroups. The 5-year event-free survival was 80.3% for 7640 consecutive patients treated on CCCG-ALL-2015 protocol between 2015 and 2019, and overall survival 91.1%. The cumulative risk of isolated CNS relapse was 1.9%, and any CNS relapse 2.7%. The isolated CNS relapse rate was significantly lower in patients with B-ALL than in those with T-ALL. Independent risk factors for isolated CNS relapse included male sex, the presence of BCRโ€“ABL1 fusion in B-ALL, and presenting leukocyte count โ‰ฅ50ร—109/L in T-ALL. Significantly lower isolated CNS relapse was associated with the use of total intravenous anesthesia during intrathecal therapy and flow cytometry examination of diagnostic cerebrospinal fluid among patients with B-ALL.

 

 

WATCH IT AGAIN!

18

 

 

SPEAKERS 


3


  Dr Tang Jing Yan, MD, Ph.D

   Department of Hematology/Oncology
   Shanghai Childrenโ€™s Medical Center
   Key Laboratory of Pediatric Hematology & Oncology of China Ministry of Health
   Shanghai Children's Medical Center
   Shanghai, China
2

 

Dr Shen Shu Hong, MD, Ph.D

Department of Hematology and Oncology
Shanghai Children's Medical Center
Shanghai Jiaotong University School of Medicine
Key Laboratory of Pediatric Hematology & Oncology of China Ministry of Health
National Childrenโ€™s Medical Center
Shanghai, China

 

prasad iyer



Dr Cai Jiao Yang, MD. Ph.D

Attending physician
Department of Hematology and Oncology
Shanghai Children's Medical Center
Shanghai, China